We specialize in creating precise investment opportunities in the biotechnology space. Our first ETF, the Loncar Cancer Immunotherapy ETF (CNCR) is listed on Nasdaq.

What’s NEW

Investing in Innovators

The CNCR ETF basket contains 25 companies, each with a unique perspective to cancer research.  Watch our exclusive series of CEO interviews to learn more about the Cancer Immunotherapy ETF’s components and the important work these companies do.

Gene editing is a paradigm shift in the field of cell therapy, immuno-oncology, and medicine in general and that’s where Cellectis is trying to make the point." − André Choulika Chairman & CEO, CEllectis

Cancer Immunotherapy ETF